Latest news from The Angelman Biomarkers and Outcome Measures Alliance (A-BOM) on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/angelman-biomarkers-and-outcome-measures-alliance-and-roche-begin-patient-centered-qualitative-research-to-inform-potential-outcome-measures-for-angelman-syndrome-clinical-trials/?sc=rsin /articles/angelman-biomarkers-and-outcome-measures-alliance-and-roche-begin-patient-centered-qualitative-research-to-inform-potential-outcome-measures-for-angelman-syndrome-clinical-trials/?sc=rsin Thu, 22 Jun 2017 09:00:17 EST A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has teamed up with F. Hoffmann-La Roche Ltd, (Roche), one of the world's largest pharmaceutical and diagnostics companies, in the first phase of a study that will support the design of human clinical trials and treatment development for the disorder. The Angelman Biomarkers and Outcome Measures Alliance (A-BOM)